Natdox-LP Caution For Usage

Incompatibilities: This medicinal product must not be mixed with other medicinal products except those mentioned in Description.
Special precautions for disposal and other handling: Parenteral products should be inspected virtually for particulate matter and discoloration prior to administration whenever solution and container permit.
Caution must be exercised in handling doxorubicin hydrochloride liposome Injection solution. The use of gloves is required. If doxorubicin hydrochloride liposome Injection comes into contact with skin or mucosa, wash immediately and thoroughly with soap and water. Doxorubicin hydrochloride liposome Injection must be handled and disposed of in a manner consistent with that of other anticancer medicinal products in accordance with local requirements.
Determine the dose of doxorubicin hydrochloride liposome Injection to be administered (based upon the recommended dose and the patient's body surface area). Take the appropriate volume of doxorubicin hydrochloride liposome Injection up into a sterile syringe. Aseptic technique must be strictly observed since no preservative or bacteriostatic agent is present in doxorubicin hydrochloride liposome Injection. The appropriate dose of doxorubicin hydrochloride liposome Injection must be diluted in 5% (50 mg/ml) glucose solution for infusion prior to administration. For doses < 90 mg, dilute doxorubicin hydrochloride liposome Injection in 250 ml, and for doses ≥ 90 mg, dilute doxorubicin hydrochloride liposome Injection in 500 ml. This can be infused over 60 or 90 minutes as detailed in Dosage & Administration.
Use only once or discard any remaining portion for preparations not containing any antimicrobial agent.
The use of any diluent other than 5% (50 mg/ml) glucose solution for infusion, or the presence of any bacteriostatic agent such as benzyl alcohol may cause precipitation of doxorubicin hydrochloride liposome Injection.
II is recommended that the doxorubicin hydrochloride liposome Injection infusion line be connected through the side port of an intravenous infusion of 5% (50 mg/ml) glucose. Infusion may be given through a peripheral vein. Do not use with in-line fillers.